News of Note—New CRISPR R&D head; Homology raises $83.5M; Cellectar collaboration

AZ's cancer head jumps ship as Homology gets a big series B and Cellectar signs a Swiss biotech deal.

> After jumping ship from a troubled AstraZeneca, its former head of oncology, Tony Ho, M.D., has climbed aboard preclinical gene editing biotech CRISPR Therapeutics. He becomes EVP and head of R&D at the company and will oversee its global research efforts across all therapeutic areas. Release

> Homology Medicines has got off an impressive $83.5 million series B financing round for work on its in vivo gene editing tech in rare genetic diseases. It had help from a host of VCs, including Deerfield Management, Maverick Ventures, Novartis, 5AM Ventures, ARCH Venture Partners, and many more. Statement

> Cancer biotech Cellectar Biosciences has penned a new collaboration with Swiss biopharma Avicenna Oncology. The pair will work together on new phospholipid drug conjugates, combining Cellectar’s phospholipid ether delivery platform with Avicenna’s cytotoxic payloads. Release

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Suggested Articles

Nimbus promoted Jennifer Rocnik, Ph.D., to vice president of biology and Alan Collis, Ph.D., will serve as vice president of clinical development.

Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.

The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.